Spyre Therapeutics, Inc. (SYRE)
(Real Time Quote from BATS)
$15.06 USD
-0.90 (-5.64%)
Updated Aug 7, 2025 11:38 AM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SYRE 15.06 -0.90(-5.64%)
Will SYRE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SYRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SYRE
Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know
How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34%
SYRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect?
Other News for SYRE
Decoding Spyre Therapeutics Inc (SYRE): A Strategic SWOT Insight
Spyre Therapeutics GAAP EPS of -$0.49 beats by $0.28
Spyre Therapeutics Inc (SYRE) Q2 2025 Earnings: EPS of -$0.49 Beats Estimate, Reports $36. ...
Spyre Therapeutics reports Q2 EPS (49c), consensus (71c)
First Week of August 15th Options Trading For Spyre Therapeutics (SYRE)